A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875

NCT04202705 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: SYD1875

Sponsor

Byondis B.V.